Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model
- PMID: 11858863
- DOI: 10.1016/s0264-410x(01)00492-3
Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model
Abstract
We report the construction of chimeric DNA vaccine vectors in which secretory signal sequence derived from tissue plasminogen activator (TPA) was fused to the full length (pCMVTE) or 398 amino terminal amino acids (pCMVTdeltaE) of Japanese encephalitis virus (JEV) envelope (E) protein. Transfection studies indicate that E protein expressed from pCMVTdeltaE-transfected cells but not pCMVTE-transfected cells is secreted into the culture medium. Analysis of the potency of various DNA vaccine constructs in a murine intracerebral (i.c.) JEV challenge model indicates that pCMVTdeltaE confers the highest level (71%) of protection. Immunization with pCMVTdeltaE induces a mixed Th1 and Th2 T helper cell response while immunization with plasmids encoding nonsecretory forms of E protein induces a Th1 T helper response. Only low levels (<1:20) of virus neutralizing antibody titres were observed in DNA vaccinated mice which did not increase further after i.c. JEV challenge. Thus, immunization with a plasmid encoding secretory E protein results in an altered cytokine response and better protection against i.c. JEV challenge than that conferred by immunization with plasmids encoding nonsecretory forms of E protein. We also demonstrate that unlike peripheral JEV challenge, i.c. JEV challenge does not result in an increase in anamnestic antibody response suggesting that other components of immune system such as cytotoxic T cells and T helper cells contribute to protection against i.c. JEV challenge of DNA vaccinated mice.
Similar articles
-
Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice.J Virol. 2003 Apr;77(7):4248-60. doi: 10.1128/jvi.77.7.4248-4260.2003. J Virol. 2003. PMID: 12634382 Free PMC article.
-
Immune responses to Japanese encephalitis virus.Curr Top Microbiol Immunol. 2002;267:91-103. doi: 10.1007/978-3-642-59403-8_5. Curr Top Microbiol Immunol. 2002. PMID: 12083002 Review. No abstract available.
-
Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.Vaccine. 2000 May 26;18 Suppl 2:26-32. doi: 10.1016/s0264-410x(00)00038-4. Vaccine. 2000. PMID: 10821970 Review.
-
Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies.Vaccine. 1999 Aug 20;18(1-2):68-75. doi: 10.1016/s0264-410x(99)00180-2. Vaccine. 1999. PMID: 10501236
-
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice.J Virol. 1998 Jan;72(1):191-200. doi: 10.1128/JVI.72.1.191-200.1998. J Virol. 1998. PMID: 9420215 Free PMC article.
Cited by
-
Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants.Front Immunol. 2024 Jan 19;15:1307546. doi: 10.3389/fimmu.2024.1307546. eCollection 2024. Front Immunol. 2024. PMID: 38361945 Free PMC article.
-
Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein.J Biomed Res. 2016 May;30(3):209-16. doi: 10.7555/JBR.30.20140157. Epub 2015 Jul 12. J Biomed Res. 2016. PMID: 27533931 Free PMC article.
-
Tailoring a Combination Preerythrocytic Malaria Vaccine.Infect Immun. 2015 Dec 14;84(3):622-34. doi: 10.1128/IAI.01063-15. Infect Immun. 2015. PMID: 26667840 Free PMC article.
-
Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters.Virol J. 2011 Aug 2;8:382. doi: 10.1186/1743-422X-8-382. Virol J. 2011. PMID: 21806845 Free PMC article.
-
DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.PLoS One. 2011;6(7):e20528. doi: 10.1371/journal.pone.0020528. Epub 2011 Jul 11. PLoS One. 2011. PMID: 21779317 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources